Last reviewed · How we verify

NCT02826330: MAGIC

Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease

Completed Last updated 11 October 2019
What this trial tests

trial testing biomarkers in Crohn's Disease in 240 participants. Completed in 3 April 2019.

Timeline
3 October 2013
Primary endpoint
3 April 2019
3 April 2019

Quick facts

Lead sponsorUniversity Hospital, Lille
StatusCompleted
Study typeOBSERVATIONAL
Enrollment240
Start date3 October 2013
Primary completion3 April 2019
Estimated completion3 April 2019
Sites10 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Lille

Who can join

Adults 8 to 50, any sex, with Crohn's Disease or Genetic Predisposition. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Transversal multicentric French study on the microbiota in patients with Crohn's disease and their first degree healthy relatives The primary objective is the comparison of microbiota between patients with CD, healthy controls non genetically linked and first degree healthy relatives of patients with CD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of biomarkers

Trials testing the same drug.

Other recruiting trials for Crohn's Disease

Currently open trials in the same condition.

Other University Hospital, Lille trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02826330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing